Michael Shawn Moran - 27 Sep 2021 Form 3 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)

Role: EVP, Chief Commercial Officer
Signature: /s/ Brian Cahill, Attorney-in-Fact
Issuer symbol: EGRX
Transactions as of: 27 Sep 2021
Net transactions value: $0
Form type: 3
Filing time: 07 Oct 2021, 19:03:12 UTC
Next filing: 07 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	EGRX	Common Stock						24,268	27 Sep 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	EGRX	Employee Stock Option (right to buy)							27 Sep 2021	Common Stock	10,000	$66.32	Direct	F2
holding	EGRX	Employee Stock Option (right to buy)							27 Sep 2021	Common Stock	27,000	$84.92	Direct	F2
holding	EGRX	Employee Stock Option (right to buy)							27 Sep 2021	Common Stock	5,000	$59.14	Direct	F3
holding	EGRX	Employee Stock Option (right to buy)							27 Sep 2021	Common Stock	1,594	$41.37	Direct	F4
holding	EGRX	Employee Stock Option (right to buy)							27 Sep 2021	Common Stock	37,500	$59.79	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	20,828 of the shares represent restricted stock units ("RSU") awards. The RSUs shall vest: 253 RSUs on January 7, 2022; 563 RSUs on January 29, 2022; 562 RSUs on January 29, 2023; 3,750 RSUs on each of January 5, 2022, January 5, 2023 and January 5, 2024; and 2,050 RSUs on each of February 2, 2022, February 2, 2023, February 2, 2024 and February 2, 2025, subject to the Reporting Person's continuous service through each vesting date.
F2	The options are fully vested and exercisable.
F3	One fourth (1/4th) of the shares underlying the option vested on January 7, 2019, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date.
F4	The option grant was initially 4,500 shares of which one fourth (1/4th) of the shares underlying the option vested on January 29, 2020, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date.
F5	One fourth (1/4th) of the shares underlying the option vested on January 5, 2021, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date.